

1 **Intraoperative Plasma Proteomic Changes in Cardiac Surgery: In Search of**
2 **Biomarkers of Post-operative Delirium**

3

4 Kwame Wiredu^{1,2}, Sean O'Connor³, Erika Monteith³, Brooke Brauer⁴, Arminja N.
5 Kettenbach^{4,5}, Hildreth R. Frost^{5,6}, Shahzad Shaefi^{3,7}, Scott A. Gerber^{1,4,5}

6

7 ¹Department of Molecular and Systems Biology, Geisel School of Medicine at

8 Dartmouth, Lebanon, NH

9 ²Program in Quantitative Biomedical Sciences, Geisel School of Medicine at Dartmouth,

10 Lebanon, NH

11 ³Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess

12 Medical Center, Boston MA

13 ⁴Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth,

14 Lebanon, NH

15 ⁵Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH

16 ⁶Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth,

17 Lebanon, NH

18 ⁷Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School,

19 Boston MA

20

21 Corresponding author: Scott A. Gerber, Professor of Molecular and Systems Biology,

22 Scott.A.Gerber@Dartmouth.Edu, 1 Medical Drive, Lebanon NH 03756

23

24 **Running title:** Biomarkers of Delirium After Cardiac Surgery

25

26 **Abbreviations:** CABG – coronary artery bypass grafting; CAM – confusion assessment

27 method; CPB – cardiopulmonary bypass; POD – post-operative delirium; SPS-MS –

28 synchronous precursor selection – mass spectrometry; TMT – tandem mass tagging

29

30 **Keywords:** biomarker discovery, delirium, mass spectrometry, plasma, proteomics

31

32 **Word count:**

33 Abstract: 202 / 200

34 Clinical significance: 159 / 200

35 Text: 4951

36 References: 2146

37 Figures and Table: 1195

38

39

40

41

42

43

44

45

46

47 **Abstract**

48 **Purpose**

49 Delirium presents a significant healthcare burden. It complicates post-operative care in
50 up to 50% of cardiac surgical patients with worse hospital outcomes, longer hospital
51 stays and higher overall cost of care. Moreover, the nature of delirium following cardiac
52 surgery with cardiopulmonary bypass (CPB) remains unclear, the underlying
53 pathobiology is poorly understood, status quo diagnostic methods are subjective, and
54 diagnostic biomarkers are currently lacking.

55

56 **Objective**

57 To identify diagnostic biomarkers of delirium and for insights into possible neuronal
58 pathomechanisms.

59

60 **Experimental design**

61 Comparative proteomic analyses were performed on plasma samples from a nested
62 matched cohort of patients who underwent cardiac surgery on CPB. A targeted
63 proteomics strategy was used for validation in an independent set of samples.

64 Biomarkers were assessed for biological functions and diagnostic accuracy.

65

66 **Results**

67 47% of subjects demonstrated delirium. Of 3803 total proteins identified and quantified
68 from patient plasma samples by multiplexed quantitative proteomics, 16 were identified
69 as signatures of exposure to CPB, and 11 biomarkers distinguished delirium cases from

70 non-cases (AuROC = 93%). Notable among these biomarkers are C-reactive protein,
71 serum amyloid A-1 and cathepsin-B.

72

73 **Conclusions and clinical relevance**

74 The interplay of systemic and central inflammatory markers shed new light on delirium
75 pathogenesis. This work suggests that accurate identification of cases may be
76 achievable using a panel of biomarkers.

77

78 **Statement of Clinical Relevance:**

79 The acute implication of delirium is well-documented, yet the true extent of the
80 consequences beyond the immediate post-operative period has yet to be fully known.
81 Despite its impact on the geriatric population, delirium remains underdiagnosed.
82 Correctly identifying cases remain a challenge in clinical practice: the arbitrary and
83 subjective nature of current diagnostic tools, such as the confusion assessment method,
84 underscores the urgent need for diagnostic biomarkers. The clinical usefulness of
85 delirium biomarkers extend beyond the objective identification of cases. Delirium
86 biomarkers will also be useful for risk stratification, long-term follow-up of patients and
87 may offer insights into possible etiologies that underpin the condition. In this report, we
88 found systemic markers of inflammation with well-established association with delirium,
89 as well as new biomarkers that shed new light on the condition. Although validation in a
90 larger cohort is the necessary next step, our efforts lay the groundwork for future studies
91 and highlight new frontiers in delirium research yet to be explored.

92

93 **Introduction**

94 Delirium remains under-diagnosed in clinical practice[1-3]. Characterized by acute
95 fluctuations in consciousness, deficits in attention and impairments in cognition not
96 explained by a pre-existing neurocognitive disorder, delirium is etiologically
97 heterogenous with a particularly high incidence after cardiac surgery[4, 5]. Following
98 cardiac surgery, it complicates post-operative care in up to 50% of patients with
99 increased length of hospitalization, increased mortality and higher overall cost of
100 care[6]. In the long term, post-cardiotomy delirium patients are at increased risk of many
101 complications, including re-admissions [7], cognitive decline [8-11], functional
102 impairments [12], and stroke [13, 14], to mention a few. Clearly, delirium presents a
103 significant healthcare burden on society. The true extent of the consequences beyond
104 the immediate post-operative period remains unknown. Thus, the accurate identification
105 of subjects for optimal care in the immediate post-operative period and for long-term
106 follow-up is likely to exert a significant positive impact on patient care and costs if
107 implemented successfully.

108

109 Unfortunately, many patients with delirium are missed [15, 16], an observation that is
110 partly due to the subjective and variable nature of the current diagnostic approach.
111 Efforts to improve recognition and accurate case identification has seen a steady rise in
112 recent years, although a small fraction of these attempts has focused on biomarker
113 discovery. Most of these biomarker studies also employed targeted quantification
114 strategies for a sub selected list of genes or proteins, an approach that is inherently

115 biased and blinded to potentially novel factors involved in the etiology or consequences
116 of delirium [17][manuscript].

117
118 Challenges with delirium biomarker discovery are due, in part, to the lack of clarity
119 regarding the underlying pathophysiology of the condition. While a one-size-fits-all
120 explanation of delirium may be oversimplified, neuroinflammation induced by system-
121 wide activation of an inflammatory cascade remains the prevailing mechanistic
122 hypothesis[18, 19]. This is supported by recent untargeted and semi-targeted
123 approaches that sought to study the proteome of human biofluids[20-27], although
124 neuroendocrine and circadian dysregulation have also been reported[18]. The emerging
125 focus on signaling and inflammatory markers necessitate biomarker discovery
126 approaches that focus on the low-abundance proteome, using analytical platforms with
127 the multiplexing capability and the requisite sensitivity to detect small changes in
128 proteomic signatures.

129
130 In the present work, we comprehensively profiled the plasma proteome of subjects at
131 baseline and post-cardiotomy for an untargeted analysis of the plasma proteome. We
132 included abundant protein immunodepletion and peptide fractionation to enhance signal
133 from the low abundance plasma proteome. Using independent set of samples, we
134 validated candidate biomarkers at three time points (at baseline, post-bypass and post-
135 operative) in order to understand the changing trajectories of these biomarkers over
136 time as they relate to case identification. Finally, we demonstrate the diagnostic
137 potential of a panel of candidate biomarkers, the accuracy of their use in discriminating

138 cases from non-cases and the temporal association between intra-operative events and
139 changes in biomarker levels.

140

141

142

143 **Results:**

144 *Clinical Profile of Study Participants*

145 Subjects ($n = 15$) were selected from the parent study[28], which was a parallel group
146 randomized controlled trial that enrolled 100 patients at Beth Israel Deaconess Medical
147 Center (BIDMC), between July 2015 and July 2017. Delirium cases and non-delirium
148 controls were age- and sex-matched (**Table 1**). There was no difference in baseline
149 neurocognition between cases and non-cases, and the proportion of patients who
150 received hyperoxic intraoperative treatment was comparable. There were no significant
151 differences with regards to demographics, medical co-morbidities, pre-operative
152 medications, or surgical characteristics. Details of the clinical characteristics of study
153 subjects were reported previously[28].

154

155 *Discovery Phase of Biomarker Workflow*

156 Using a multiplexed isobaric tagging (TMT)-based design, plasma samples at baseline
157 and on post-operative day 1 from 7 delirium cases (CAM+) and 8 non-delirium controls
158 (CAM-) were comprehensively profiled (**Figure 1**). For precision, samples selected for
159 the discovery phase of the study were analyzed in duplicates, for a total $n = 60$ samples,
160 which necessitated the analysis of seven separate, batched multiplexes. To control for

161 technical variation between batches, two channels in each of the seven 11-plex TMT
162 sets were reserved as bridge samples using equal amounts of a pooled plasma sample.
163 We fractionated the TMT-labeled peptides using off-line HPLC on a pentafluorophenyl
164 (PFP) column as described previously[29] into 48 fractions, which were subsequently
165 concatenated into 12 and analyzed by LC-MS/MS on an Orbitrap Fusion Lumos Tribrid
166 instrument platform.

167
168 A collective total of 17,540 unique peptides from 3,803 proteins were identified from all
169 seven multiplexes. An analysis of the number of proteins from each batch, separated
170 into a binary group based on the corresponding number of peptides used in the
171 identification of these proteins, demonstrates that our data are clearly dominated by so-
172 called “one-hit proteins,” or proteins identified by a single peptide (**Figure 2A**). Often,
173 single-peptide protein identifications are excluded from downstream analysis due to the
174 increased risk of false protein identifications associated with single-peptide protein
175 assignments. However, excluding all one-hit proteins can be a huge informational cost
176 as some of these proteins may be biomarkers of interest.

177
178 *One-hit Proteins and Deep Learning for Confident Protein Identification:*

179 To examine this further, we differentiated one-hit proteins identified only in single
180 batches of experiments from those identified consistently across multiple batches. We
181 reasoned that identified one-hit proteins consistently identified in multiple independent
182 analyses are less likely to be false identifications, especially if their consistent
183 identification is based on the same unique peptide. These one-hit proteins warrant

184 additional peptide-centric information for protein inference beyond the sequences of the
185 single peptides. **Figure 2B** displays the number of proteins identified in any given
186 number of collective batches. Of the 3803 total proteins (**figure 2B**, cumulative batch
187 ≤ 7), 51% ($n = 1941$ proteins) were identified based on a single peptide. While the
188 number of proteins identified based on 2 or more peptides increased with increasing
189 number of collective batches, the number of one-hit proteins remained fairly consistent.
190 In particular for cumulative batches three to seven, we found 1698 one-hit proteins that
191 were present in all of them.

192
193 To enhance the confidence in the identity of these one-hit proteins and minimize false
194 positive identifications, we employed chromatographic retention time (RT) as additional
195 peptide-centric information and orthogonal to their identification by tandem mass
196 spectrometry. Here, we considered a peptide as confidently identified if, in addition to
197 being a high-scoring peptide by PSM, the observed RT also falls within the RT window
198 expected for that peptide and its corresponding experimental batch conditions. For
199 example, K.GTEAAGAMFLEAIPMSIPPEVK.F, a unique peptide from alpha-1-
200 antitrypsin, A1AT_HUMAN (**figure 2C, supplemental figure 1**, blue rectangles) shows
201 consistent RTs, regardless of the experimental batch or sample fraction the peptide was
202 detected. On the other hand, K.GTEDFIVESLDASFR.Y (**figure 2C, supplemental**
203 **figure 1**, red rectangles) is the only peptide-evidence that translocon-associated protein
204 subunit alpha, SSRA_HUMAN – a one-hit protein – was detected in experimental batch
205 2.
206

207 To determine the RT window expected for these single peptides given the LC-MS
208 conditions of their respective experimental batches, we trained a deep learning-based
209 RT predictor, the DeepRT+ [30], using 80% of the RT of consistently identified peptides
210 for a given experimental batch. We tested the prediction accuracy of the DeepRT+
211 model with the remaining 20% of the training data and subsequently used the final
212 model to predict the RT of one-hit proteins. We assessed performance of the RT
213 prediction using the coefficient of determination, R^2 , and $\Delta t_{95\%}$, the minimum time
214 window containing deviations between the observed and the predicted RT for 95% of
215 the peptides (**Figure 2D** and **Supplemental Figure 2**). We found the RT of 495 unique
216 one-hit peptides fell within the $\Delta t_{95\%}$ metric (**Table 2**) and were thus included to a final
217 total of 1731 proteins used for downstream analysis (**Figure 2E**). The dynamic range of
218 all proteins spans 6.3 orders of magnitude and confirms signal from a wide range of
219 abundances in the plasma proteome (**Figure 2F**).

220

221 *Protein Feature Selection and Differential Abundance Analyses*

222 To determine the subset of these 1731 proteins that are most important in discriminating
223 plasma profiles of cases and from non-cases and between baseline and post-operative
224 timepoints, we employed an elastic net regularized regression approach[31]. We found
225 47 and 64 proteins as signatures of surgical exposure and of delirium, respectively.
226 Principal component analysis (PCA) of study subjects using the subset of protein
227 features demonstrates that delirium cases cluster separately, with marginal overlap
228 between non-delirium controls and baseline samples (**Figure 3A**). Additionally, plasma
229 profiles of cases and non-cases are clearly separable post-operatively, although they

230 were indistinguishable at baseline (**Figure 3B**). This strongly suggests a temporal
231 relationship between post-operative changes in proteomic signatures and subjects'
232 surgical exposure and/or related intra-operative physiological events.

233

234 Furthermore, we quantified the extent of changes in biomarker levels before and after
235 surgery (**Figure 3C**) and between cases and non-cases (**Figure 3D**). When using the
236 proteins identified as a signature of delirium (**Figure 3D**), we observed a diagnostic
237 accuracy of 93% in discriminating cases from non-cases (**Figure 3E**). Functional
238 analysis of the biomarker panel for biological processes shows acute inflammatory
239 response and activation of the immune system as the most significantly enriched
240 functional pathways, predominantly in the extracellular region (**Figure 3F** and
241 **Supplemental Figure 3**).

242

243 *Biomarker Verification*

244 For further evaluation of peri-operative proteomic differences between cases and non-
245 cases, an independent set of plasma samples was used to verify biomarkers discovered
246 *a priori* (**Figure 4**). Here, we used parallel reaction monitoring (PRM) as the targeted
247 approach and employed label-free quantification (LFQ) as orthogonal methods different
248 from the TMT approach used in the discovery phase. To ascertain the degree to which
249 changes in protein concentration in the complex background of plasma are quantifiable,
250 we artificially modified six biological replicates of a pooled plasma sample with the
251 addition of exogenous proteins: (1) equal amounts of a non-human
252 (*Schizosaccharomyces pombe*) homolog of the serine/threonine-protein kinase Chk2

253 (CDS1 in *S. pombe*); and (2) increasing concentrations of heavy-labeled AQUA
254 peptides[32, 33] of human condensin-2 complex subunit H2 (CNDH2). From this
255 experiment, we estimate a limit of quantification of ~1fmol on column (**Figure 5A**), with
256 negligible impact on target protein quantification due to matrix effects from large (16-
257 fold) variations in the concentration of a non-target protein in the matrix (**Supplemental**
258 **Figure 4**).

259
260 For candidate biomarker verification, we developed parallel reaction monitoring (PRM)
261 methods through an iterative optimization process (**Supplemental Figure 5**). We
262 monitored 153 unique peptide sequences (212 total precursor ions including the
263 observed range of charge states) from the union of 18 differentially abundant proteins
264 as PRMs that were distributed across the entire LC-PRM elution gradient (**Figure 5B**).
265 For example, we monitored the abundance of the peptide ESDTSYVSLK from C-
266 reactive protein as a doubly-charged ion via five individual y-ions in our PRM method
267 via Skyline (**Figure 5C**) in each verification sample. The PRM methods we employed
268 required the following minimum criteria for peptide quantification: a consistent minimum
269 of 5 transitions in all samples, a minimum dot-product of 95% and manual inspection of
270 all peaks for interference-free co-eluting transitions with distinct peak boundaries. 65
271 precursors from 13 proteins met these criteria for downstream analysis (**Supplemental**
272 **Table 3**). Unsupervised clustering based on the quantification of these candidate
273 biomarkers shows that post-operative samples aggregate separately from post-bypass
274 and baseline samples (**Figure 5D**). This is further confirmed by statistical comparison of

275 biomarker levels between the sampling timepoints (**Figure 5E** and **Supplemental**
276 **Figure 6**).

277
278 Seven biomarkers (A2GL, AACT, CH3L1, CRP, LBP, MA1A1 and SAA1/SAA2) were
279 significantly increased at post-operative day one (PO1) relative to baseline in this
280 validation cohort. Four razor peptides were shared between SAA1 and SAA2. However,
281 no peptides unique to either SAA1 or SAA2 met the minimum quantification criteria for
282 PRM verification. Similarly, none of the precursor peptides of CAH3, EFNA1, FGL1 or
283 PEPA4 met PRM quantification criteria. Regardless of statistical significance, we
284 observe that these candidate biomarker levels show a consistent increase in abundance
285 between baseline and PO1 (**Supplemental Table 3**). This panel of differentially
286 abundant candidate biomarkers yields a discriminatory power of 96% (84.9 – 100%)
287 between cases and non-cases (**Figure 5F**).

288

289

290

291 **Discussion**

292 This unbiased proteomic analysis of samples from a prior nested case-control study is
293 the deepest unbiased plasma proteomic profiling for potential biomarkers of delirium to
294 date. We employed a rectangular biomarker workflow[34] to both discover and verify
295 biomarkers of post-operative delirium on a single mass spectrometry platform without
296 the use of traditional affinity-based verification methods. Dominated by one-hit wonders,
297 our focus on the low-abundance proteome presented us with the challenge of protein

298 inference, for which we applied deep learning to recover pertinent orthogonal peptide
299 chemical information and salvage a significant number of these one-hit proteins.

300 We identified 3808 proteins by isobaric quantitative multiplexed proteomics, 16 of which
301 were differentially abundant post-operatively from baseline levels, and 11 of which were
302 differentially abundant in cases relative to controls. This includes proteins with well-
303 documented associations with delirium, such as CRP, CH3L1, AACT, TIMP1, as well as
304 new ones not previously associated with delirium, including SAA, CATB and PEPA3.

305 Using an independent set of samples, we attempted to verify the union of these
306 candidate biomarkers and found a 96% accuracy in correctly identifying delirium
307 patients for those for which quantification was possible. Collectively, our findings show a
308 temporal association between intra-operative events (i.e., surgical insult, administered
309 anesthesia, etc.) and proteomic changes associated with phenotypic delirium.

310
311 The prevailing mechanistic hypothesis of delirium is one of acute neurocognitive
312 disruption triggered by system-wide inflammation[18, 19]. In our study, functional
313 analysis of the post-operatively dysregulated biomarkers suggests a system-wide
314 activation of the inflammatory cascade and related immunological reactions. Data on
315 the associations between delirium and acute-phase reactants (APR) such as CRP is
316 ubiquitous[20, 35-38]. Although known APRs correlate well with the severity of
317 inflammation, their usefulness as biomarkers is limited as they are not specific to
318 delirium. We, however, found additional acute-phase reactants that may shed a new
319 light on delirium.

320

321 Human serum amyloid A (SAA) is a collective name for a group of polymorphic proteins
322 functionally associated with high-density lipoprotein (HDL). By the regulation of their
323 synthesis, they are grouped into the acute phase isotypes (a-SAA: SAA1, SAA2 and
324 SAA3) and the constitutive isotype (c-SAA: SAA4)[39, 40]. Although predominantly
325 secreted by the liver, extra-hepatic production occurs in the brain and may be more
326 relevant in neurocognitive disorders such as Alzheimer's disease[41-44]. SAA has
327 cytokine-like effects which likely provokes blood brain barrier (BBB) dysfunction,
328 induces depressive-like behavior in mice and may impair cognition in human
329 subjects[45-48]. In the present study, we found SAA1 and SAA2 were both upregulated
330 post-operatively in delirium cases by over 5 folds (p value < 0.001). This is the first
331 mention of SAA in the context of delirium and warrants further studies to formally
332 credential this association with the condition.

333
334 The cysteine protease cathepsin B (CATB) has previously been quantified as an AD-
335 related biomarker and correlates with mini-mental state examination (MMSE) scores
336 [49-52], but its association with delirium is unknown. It is an inflammasome that
337 promotes IL-1beta maturation and secretion[52]. It also has a beta-secretase activity,
338 capable of cleaving amyloid precursor protein into amyloid beta [53]. Given that cases
339 and non-cases in our study were matched by baseline neurocognition and tMOCA
340 scores were statistically controlled for, upregulation of CATB in delirium cases may
341 indicate a common pathophysiological starting point in the continuum of neurocognitive
342 disorders, of which delirium and AD are a part. Generally recognized as the first enzyme
343 to be discovered, pepsin (PEP-A) is the native acid protease of the stomach[54]. Blood

344 pepsin is an established biomarker of gastric mucosal integrity, and plasma levels
345 correlate with the degree of mucosal damage[55-58]. Cardiac surgery and CPB places
346 enormous physiological stress on the body. Through the cholinergic anti-inflammatory
347 reflex, the body attempts to ameliorate the stress by increasing vagal tone[59-62] which
348 manifests as gastric acid production. Normally, small amounts of secreted pepsin (~1%)
349 may be found in blood and urine[63], but with increased acid production, this proportion
350 may be higher. In the discovery phase of our study, differentially abundant PEP-A levels
351 in cases relative to non-cases (1.64-fold increase, p value < 0.001) despite pre-
352 operative proton-pump inhibitor administration in the study subjects suggests a peculiar
353 association between plasma PEP-A levels and delirium. At present, we are unable to
354 explain the relationship, if any, between increased vagal tone and neuroinflammation.

355
356 The independent association between CPB and delirium remains an ongoing debate
357 and data on the relationship is conflicting. On the one hand, the use and duration of
358 extracorporeal circulation is reported to increase the risk of delirium[64-66]. Some
359 authors, on the other hand, have reported no associations between delirium incidence
360 and CPD duration[67, 68]. In our cohort, there was no statistically significant difference
361 in aortic cross-clamp time or duration of bypass between delirium cases and non-
362 cases.[28] To determine the impact of CPB in our cohort, we compared post-operative
363 plasma profiles to baseline regardless of the case/non-case status of subjects. We
364 found 16 dysregulated proteins, most of which have been characterized as non-specific
365 markers of surgical exposure[69-71]. A striking observation in our study is the
366 similarities in proteomic signatures between cases and non-cases at baseline, despite a

367 clear difference at post-operative day one. Previous studies have shown that post-
368 operative delirium cases are likely to be in a heightened pre-operative inflammatory
369 state [20, 37, 60, 72-75], which makes them more vulnerable to intraoperative stressors.
370 In our study, similarities in the levels of identified biomarkers at baseline suggests
371 otherwise.

372

373 The main strength of the present study is in its unbiased, hypothesis-generating
374 approach to identify potential biomarkers of delirium. This lays the groundwork for future
375 studies and highlights new frontiers in delirium research yet to be explored.

376 Translational utility from the research bench to the patients' bedside requires that the
377 biomarker readout in the discovery phase is independent of the measurement approach
378 used for their discovery[76]. For this reason, we validated discovered biomarkers using
379 label-free quantification, which is orthogonal to the TMT-based measurements in the
380 discovery phase of our study. Our choice of PRM-MS over traditional affinity methods
381 for validation (e.g., ELISA) is further premised on the fact that affinity methods are semi-
382 quantitative with inter-operator variability in quantification, have limited dynamic range
383 and require larger amounts of sample. In addition to the requirement for peptide
384 antigenicity, antibody cross-reactivity limits multiplexing (i.e., how many proteins can be
385 validated at a time)[77]. All proteins needing validation require antibodies, a step that
386 takes considerable amount of time to develop and can be cost-prohibitive if commercial
387 options are not available[78]. This, in fact, is a long-standing bottleneck in clinical
388 biomarker workflow[79].

389

390 Our study is, however, not without limitations. First, sample sizes for both the discovery
391 and validation phases may have limited statistical power in detecting differences in the
392 levels of many other biomarkers. In our cohort, the CAM test was administered daily
393 after surgery. In our statistical analysis, we did not correct for the effects of retesting on
394 repeated test administration in this cohort. In the discovery phase, our interest in the
395 low-abundance plasma proteome required an immunodepletion step to remove the
396 majority of the top 14 most abundant plasma proteins. The extent to which this
397 experimental step contributed to the removal of other proteins through their specific or
398 non-specific binding was not ascertained. Although isotypes SAA1 and SAA2 each had
399 unique peptides in the discovery phase, only the razor peptides met the criteria for
400 quantification in the validation phase and were thus undistinguishable. Similarly,
401 peptides from CAH3, EFNA1 and PEPA3 did not meet the minimum quantification
402 criteria for verification by PRM, and peptides from FGL1 were not detected at all in any
403 of the verification samples by PRM.

404

405 In summary, diagnostic biomarkers of delirium are urgently needed for accurate case
406 identification, long-term risk stratification and for molecular characterization of delirium.
407 In this study, we discovered a panel of biomarkers through the unbiased comparative
408 analyses of baseline and post-operative plasma samples of delirium cases and non-
409 cases. We underscored the importance of brain-specific biomarkers such as SAA and
410 CATB and their possible role in the pathophysiology of delirium. In the long-term, it is in
411 our research interests to rigorously test their associations with delirium and ascertain
412 how these biomarkers change over time in a larger independent cohort.

413

414 **Acknowledgments**

415 Funding support for this work was supplied by the Burroughs Wellcome training grant to
416 KW, the National Institutes of Health (R01 GM122846) to SAG, and K08 GM134220
417 and R03 AG060179 to SS. The heavy-labeled peptides of CNDH2 condensin subunit
418 were also provided by Dr Giovanni Bosco (Dartmouth College).

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437 **Materials and Methods:**

438 *Study Design and Patient Enrollment:*

439 Subjects in this nested case-control study were selected from the parent study, a
440 randomized double-blind trial conducted on subjects who underwent coronary artery
441 bypass grafting (CABG) with cardiopulmonary bypass (CPB) between July 2015 and
442 July 2017 at the Beth Israel Deaconess Medical Center (BIDMC) in Boston MA. The trial
443 was registered with ClinicalTrials.gov (NCT02591589, <https://clinicaltrials.gov/ct2/show/NCT02591589>, principal investigator: Shahzad Shaefi, registration date:
444 October 29, 2015). Institutional review board (IRB) approval 2014P000398/33 was
445 amended for the purposes of this current study on 09/17/2021 by the Committee on
446 Clinical Investigations at the BIDMC. Details of enrollment, subject randomization and
447 treatment allocation in the parent study are published elsewhere [28, 80]. Briefly,
448 patients aged 65 years or older who were booked for elective CABG requiring CPB
449 were eligible. The primary objective was to examine the temporal relationship between
450 intra-operative oxygen treatment and post-operative neurocognitive function as
451 measured by the telephone-based Montreal Cognitive Assessment (tMOCA) score.
452 Patients were assessed for delirium as a secondary endpoint using the confusion
453 assessment method (CAM). Patients were excluded if they were undergoing emergent
454 CABG, if they required single-lung ventilation, CABG without CPB, intraoperative
455 balloon counter-pulsation or mechanical circulatory support. All patients provide
456 informed consent. 15 subjects were randomly selected for proteomic profiling in this
457 nested case-control study. Because quantitative studies on the effect size of delirium
458

459 biomarkers using mass spectrometry is largely unexplored, formal power analysis was
460 not done.

461

462 *Sample Collection:*

463 Whole blood samples at baseline, post-bypass (P-BP) and on post-operative day one
464 (PO1) were collected into 4mL EDTA-treated tubes (BD Diagnostics) and centrifuged
465 immediately at 200g at room temperature for 10 min. Resulting plasma was stored at -
466 80°C until they were thawed for aliquots used here for proteomic profiling.

467

468 *Chemicals and Reagents:*

469 All LC-grade chemicals are marked with asterisk (*): Dithiothreitol (DTT), 4-(2-
470 hydroxyethyl)-1-piperazineethanesulfonic acid (EPPS), Tris (hydroxymethyl)
471 aminomethane (Tris), formic acid* and acetonitrile* were purchased from Sigma-Aldrich.
472 Methanol* was obtained from Fisher. Trypsin Protease, SDS, 2-iodoacetamide (IAA),
473 High Select Top14 Abundant Protein Depletion Mini Spin Columns and TMT 11 plex kit
474 were acquired from Thermo Fisher Scientific.

475

476 *Sample Preparation analysis:*

477 *Sample Immunodepletion:*

478 Buffer exchange on single-use High Select Top14 Abundant Protein Depletion mini-spin
479 columns (ThermoFisher Scientific) was performed twice using 200 µL of 50mM Tris [pH
480 8.1] / 50mM NaCl. 10 µL of each plasma sample was applied to the mini-columns,
481 incubated at -4°C with gentle end-over-end mixing for 15 min, according to

482 manufacturer's instructions. Flowthrough were collected by centrifugation at 1000g for 2
483 min into 2mL Eppendorf tubes. Concentrations of the depleted samples were obtained
484 using the Pierce BCA Protein Assay Kit (Thermo Scientific) at 562 nm absorbance per
485 manufacturer's instructions.

486

487 *Digestion and Labelling for Biomarker Discovery*

488 Depleted samples were treated with SDS (2% final) and DTT (2mM final) for denaturing
489 at 75°C for 15 min. Samples were cooled to room temperature before alkylation with IAA
490 (7mM final) at room temperature in darkness for 30 min and quenched with DTT
491 (additional 2mM final) for 10 minutes. Proteins were isolated by single-pot solid-phase-
492 enhanced sample preparation (SP3) and digested to peptides in EPPS buffer overnight
493 at 30°C with 1:50 w/w trypsin (Promega™). Tryptic peptides were labeled with TMT-11
494 plex reagent for 1 hr according to manufacturer's instructions. Two channels in each set
495 of TMT-11 plex were reserved for pooled plasma to be used as bridge samples for
496 technical control. Labeling efficiency of at least 95% was confirmed on a 1-hr gradient
497 before pooling. Labeled tryptic peptides were then desalted on an OASIS μHLB
498 (Waters) and subsequently dried by vacuum centrifugation prior to off-line HPLC
499 fractionation on a pentafluorophenyl (PFP) column as described previously [29]. 48
500 fractions were concatenated into 12 fractions for LC-MS/MS analysis. All samples were
501 prepared in duplicates.

502

503

504

505 *Digestion for Biomarker Validation*

506 Equal amounts of recombinant purified CDS1 protein were added to each depleted
507 sample before treatment with SDS (2% final) and DTT (2mM final) for denaturation and
508 alkylation as described above. Proteins were isolated by single-pot solid-phase-
509 enhanced sample preparation (SP3) and digested to peptides in 50mM ammonium
510 bicarbonate buffer overnight at 30°C with 1:50 w/w trypsin (Promega™). In a separate
511 experiment to check for signal linearity, increasing concentrations of heavy-labeled
512 peptides of CNDH2 condensin subunit were added to the samples at this point. Tryptic
513 peptides were desalted on an OASIS µHLB (Waters) and dried by vacuum
514 centrifugation. All samples were run in duplicates.

515

516

517 *LC-MS/MS*

518 All data were acquired on an Orbitrap Fusion Lumos Tribrid instrument (ThermoFisher
519 Scientific, San Jose, CA) equipped with EASY-nanoLC 1200 ultra-high pressure liquid
520 chromatograph (ThermoFisher Scientific, Waltham, MA). Dried peptides were
521 resuspended in 5% methanol / 1.5% formic acid and injected onto a 35-cm long / 100-
522 µm (inner diameter) in-house pulled analytical column packed with Reprosil C18
523 stationary phase particles. Discovery samples were separated on 120-minute gradient,
524 and validation samples on a 60-min gradient, at 350nL/min flow rate. Acquisition
525 parameters included 120,000-resolution at MS1, AGC target value of 5.0×10^5 , scan
526 range of 350 – 1250 m/z and maximum injection time of 100ms. For the TMT-labeled
527 peptides, the top eight MS2 peaks were selected for further fragmentation at 55%

528 normalized high-collision energy (HCD) via SPS-MS3 for quantification of reporter ions
529 in the scan range of 110 – 500 m/z. For the label-free peptides in the validation phase,
530 MS2 scans were generated at 30,000 resolution and AGC value of 2.5×10^5 , using 30%
531 normalized collision energy (HCD).

532

533 *Bioinformatics*

534 *Peptide Spectral Matching:*

535 Acquired data (in .raw format) were searched using COMET [81] against a target-decoy
536 version of the human proteome (Uniprot, downloaded in 2020 and 2022, for the
537 discovery and validation phases respectively). The fasta for the validation phase was
538 appended with sequences from CDS1_SCHPO. Search parameters included a mass
539 tolerance of 20ppm, maximum missed cleavages of 3, carbamidomethylation of
540 cysteine as fixed modification and oxidized methionine as variable modification. In
541 addition, the mass of 229.162932 Da was added to the N-termini and lysine residues of
542 all peptides as fixed modification for the TMT data. A false discovery rate (FDR) of 1%
543 was applied at the peptide level and final list of PSMs were filtered using XCorr and
544 delta XCorr. All data were subsequently imported into R environment for statistical
545 computing (v4.1.1) and Python programming language (v3.8) for downstream analyses
546 [82, 83].

547

548 *TMT Data Wrangling and Normalization (Discovery Phase):*

549 After correcting for differential sample loading, the ratios of sample proteins to their
550 respective bridge proteins were computed. Here, data from bridge samples was used

551 for quality control and to correct for batch-to-batch technical variations. Values were
552 subsequently log-transformed and mean-centered. Data from all batches were
553 combined and analyzed for possible outlier observations using OutlierDM R Package.
554 Proteins were removed if their frequency of observation was less than half of all
555 samples. For one-hit wonders in each batch of experiment, a retention time (RT)
556 predicting model was built in Python using DeepRT+ as described by Ma, Ren [30].
557 Prediction performance was assessed with coefficient of determination (R^2) and delta-
558 $t_{95\%}$ ($\Delta t_{95\%}$). $\Delta t_{95\%}$ is the minimum time window containing deviations between the
559 observed and the predicted RT for 95% of the peptides. Peptides with RT outside the
560 $\Delta t_{95\%}$ range were excluded from downstream analysis. Missing entries in the data were
561 imputed by making random draws from the left tail of the gaussian distribution of the
562 entire log-transformed data matrix (using -2.5 SDs from the mean, width = 0.3).

563

564 *Protein Feature Selection and Differential Abundance Analyses*

565 To determine the subset of protein features that differentiated cases from non-cases, or
566 postoperative expression profiles from baseline, Elastic Net algorithm was used [31].
567 This is a regularization and feature selection method with good performance on high-
568 dimensional data (i.e., an $n \times p$ data with very large p proteins but small n samples).
569 Elastic Net is insensitive to features that dominate the matrix (e.g., albumin) and likely
570 suppress signal from low abundance predictors and skew model coefficients. In
571 addition, Elastic Net is a good choice if overfitting and multicollinearity (or protein
572 features that are highly correlated and essentially communicate the same information)
573 are a concern. Tuning parameters were achieved by grid optimization with a five-fold

574 nested cross-validation where the last fold was held out for testing. The average of
575 hyperparameters from all folds were computed and used to build the final model.

576
577 Using the subset of protein features, an unsupervised visualization of the data was
578 achieved with principal component analysis (PCA). Hierarchical clustering was
579 employed to check for reproducibility of replicate samples and inherent sample clusters,
580 and together with a heatmap, the overall protein expression patterns. Here, clustering
581 was achieved using Ward's clustering algorithm.[84] Briefly, Ward's minimum variance
582 method begins with singleton clusters and recursively merges them by minimizing the
583 total within-cluster variance as the objective function. After this point, protein values for
584 any given biological replicates were summarized as means prior to differential
585 abundance analyses. Two-way comparison for differential abundance was achieved by
586 Student's *t*-test, assuming unequal variance. Differential abundance analysis was
587 visualized with volcano plots. Because statistical comparison was done for only a
588 subset of proteins, no correction for multiple hypothesis testing was done. Proteins were
589 deemed differentially regulated between conditions if there was a statistically significant
590 *t*-test (p value cutoff ≤ 0.05) and a log₂ fold-change of at least ± 1 . This fold-change
591 cutoff was selected to prioritize a panel of biomarkers with significant changes between
592 conditions that is unlikely to be due to chance.

593

594 *PRM Label-free Data Processing (Validation Phase):*

595 Raw files were imported into Skyline v21.2.0.369 [85]. Precursor peptides with
596 modifications other than carbamidomethylation of cysteine (as fixed modification) or

597 oxidized methionine (as variable modification) were excluded. Peptide quantification
598 criteria was defined as follows: (1) consistently identified precursors across all validation
599 samples, (2) with maximum of two missed cleavages, (3) a consistent minimum of five
600 transitions, and (4) at least 0.95 dop-product with the spectral library of chromatograms.
601 All peak boundaries were manually inspected for interference-free co-eluting transitions
602 before peak areas were integrated at the MS2 level. For any given precursor peptide,
603 the five most intense fragment ions in the m/z range of 120 – 1500 were used for
604 quantification. Final dataset was exported as .csv and analyzed in R environment for
605 statistical computing (v4.1.2; R Core Team 2021). No imputations were required in the
606 validation data. Data was normalized by computing peak area ratios relative to
607 CDS1_SCHPO to correct for run-to-run variations. For each protein biomarker, Kruskal
608 Willis global test was first used followed by post-hoc Mann-Whitney U test for pairwise
609 comparisons of the normalized peak areas between the different sample collection
610 timepoints (baseline, post-bypass and post-operative day 1).

611

612

613 *Data accessibility statement:*

614 Datasets from the discovery and validation phases are available as supplemental
615 material.

616

617

618

619

620 **Figure 1 Caption: Study Design and Biomarker Discovery Workflow**

621 Biomarker discovery: a cohort of 15 subjects were selected from the parent study of 100
622 patients who underwent a non-emergent coronary artery bypass grafting (CABG) on
623 cardio-pulmonary bypass (CPB) as part of a previously published clinical trial (1,2).
624 Plasma samples of delirium cases (CAM+) and non-delirium controls (CAM-) were
625 retrieved from the biorepository for subsequent proteomic analysis (3). Samples were
626 immunodepleted, digested and labeled with multiplex isobaric quantification (TMT)
627 reagents. For each set of TMT reagents, two channels were reserved for bridge
628 samples for post-hoc batch correction (4). TMT-labeled samples were concatenated (5)
629 and additionally fractionated (6) prior to LC-MS/MS (7) for quantification at MS3 (8).
630 After peptide spectral matching and false discovery rate (FDR) curation, the final
631 dataset of 3803 proteins was quantified and analyzed for candidate biomarkers (9).

632

633

634 **Figure 2 Caption:**

635 **A.** Total number of proteins identified per batch. Bars are demarcated by the
636 number of unique peptides used for protein identification. Gray portion of each
637 bar chart represents proteins identified by only a single peptide, highlighting the
638 scope of one-hit proteins in our analysis.

639 **B.** Number of proteins identified in a cumulative number of experimental batches.
640 For example, of the 1638 total proteins identified in up to two cumulative batches
641 of experiments (cumulative batch ≤ 2), about 90% of those ($n = 1470$) were one-
642 hit proteins. The number of one-hit proteins increases only marginally with

643 increasing cumulative batches (light green portion of the green bars), in contrast
644 to proteins identified from at least two peptides.

645 **C.** Chromatographic retention times of select peptides from the discovery
646 experiment. Plot shows the consistency of retention times (RT) of
647 K.GTEAAGAMFLEAIPMSIPPEVK.F (blue rectangle), observed in two fractions
648 from multiple LC-MS runs. K.GTEDFIVESLDASFR.Y (red rectangle), on the
649 other hand, was only identified once. In the absence of additional peptides, these
650 single peptides required further information to reduce false protein assignments

651 **D.** Scatter plot of experimental and predicted RTs of peptides from experimental
652 batch 1. RTs were predicted by training a deep learning RT predictor, DeepRT+.
653 Prediction performance is assessed with R^2 and $\Delta t_{95\%}$ (red dashed lines). $up =$
654 number of unique peptides trained.

655 **E.** Selection of the final 1731 proteins for downstream differential abundance
656 analysis. Use of DeepRT+ salvaged 495 one-hit proteins that would otherwise be
657 removed from downstream analysis.

658 **F.** Dynamic range of all 1731 proteins, ranked in decreasing order of intensity. Each
659 dot represents the median intensity of all intensity values recorded for a given
660 protein across all samples. Intensity is plotted on the log-scale and spans 6.3
661 orders of magnitude between the high-abundance classical plasma proteins and
662 the low-abundance signaling proteins. Functional groups are based on Putnam's
663 classification. Red dots highlight representative members in each functional
664 group. Labels are gene names of the corresponding proteins

665

666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689

Figure 3 Caption:

- A.** Principal component analysis of all discovery samples (including replicates). Clustering is based on a subset of 64 proteins identified by the penalized regression approach (ElasticNet) for feature selection.
- B.** Hierarchically clustered heatmap of proteomic signatures of delirium cases and non-delirium controls at two time points (baseline and post-operative day 1, PO1). Post-operatively, a subset of proteins (protein cluster 2, dashed lines) shows a higher expression in cases relative to non-cases, although the expression of this subset of proteins was very similar between the two groups at baseline
- C.** Volcano plot of p -value (\log_{10} scale) vs fold-change (\log_2 scale) of the 47 proteins that explain most of the variation in proteomic profiles of the baseline and post-operative day 1 samples. Blue dot means protein is significantly different at PO1 relative to baseline by at least 2 folds (p -value cut-off = 0.05)
- D.** Volcano plot of the 64 proteins that explain most of the variation in proteomic profiles between delirium cases and non-delirium controls.
- E.** Diagnostic accuracy of the panel of 11 differentially abundant proteins that discriminate cases from non-cases.
- F.** Functional analysis of biomarkers for biological processes enriched among the panel of 11 differentially abundant proteins that discriminate cases from non-cases.

690 **Figure 4 Caption: Biomarker Validation**

691 Validation samples included baseline (*B*), post-bypass (*P-BP*) and post-operative day 1
692 (*PO1*) samples. To each unlabeled validation sample, an equimolar amount of CDS1, a
693 protein from *S. pombe* with no sequence overlap to human proteins previously
694 expressed and purified from bacteria, was added as a reference standard to control for
695 run-to-run variations. Select tryptic peptides of regulated proteins from the discovery
696 phase were targeted for quantification using via PRM-MS. Concentrations of each
697 biomarker were analyzed for changes across the sampling time points (*B*, *PB*, *PO1*).
698 Hypothetical data are depicted as exemplars.

699

700

701 **Figure 5 Caption:**

702 **A.** Normalized peak areas of CNDH2_HUMAN condensin subunit with increasing
703 concentrations of its heavy-labeled stable isotope standards spiked into a
704 background matrix of plasma. Grey area is the 95% confidence band of the
705 regression line of fit: $y = (12.84 + 33.25x[\text{CNDH2}]) \times 10^6$

706 **B.** Number of precursors monitored concurrently during five-minute windows across
707 the 78-minute gradient for used for validation experiments.

708 **C.** Representative extracted ion chromatogram (XIC): the five most intense
709 fragment ions of the CRP_HUMAN peptide ESDTSYVSLK, co-eluting at
710 28.3mins. All other peptides were quantified similarly with a minimum of five
711 transitions consistent across all samples, a minimum dot product (dotp) of 95%

712 and manual inspection for distinct peak boundaries and interference-free
713 transitions.

714 **D.** Principal component analysis of all validation samples. Notable here is the
715 clustering of post-bypass samples together with the baseline, signaling similar
716 proteomic signatures between the two timepoints.

717 **E.** Representative plot of differential abundance analysis of validated proteins for
718 the candidate biomarker C-reactive protein (CRP), showing changes across the
719 three sample collection time points: baseline, post-bypass (P-BP) and post-
720 operative day one (PO1)

721 **F.** ROC analysis of the discriminatory power of the validated panel of biomarkers

722

723

724 **Table Captions:**

- 725 1. Selected baseline characteristics of study subject in the discovery phase.
- 726 Delirium cases were age- and sex-matched to non-delirium controls. Details of all
- 727 clinical characteristics of study subjects are reported elsewhere (Shaefi et al.,
- 728 2021). Abbreviations: tMOCAs: telephone-based Montreal Cognitive Assessment
- 729 test for Dementia
- 730 2. Summary of DeepRT+ training parameters and results of prediction assessment.
- 731 Training. Given that each batch of sample has unique LC-MS experimental
- 732 conditions that uniquely impact RT, seven different models were built for each of
- 733 the seven batches of experiments. Abbreviations: RT (min): minimum RT for the
- 734 batch; RT (max): maximum RT; aa: amino acid; up (training): number of unique
- 735 peptides trained; up (predicted): number of unique peptides whose RTs were
- 736 predicted; R^2 : coefficient of determination = correlation coefficient for bivariate
- 737 analysis; $\Delta t_{95\%}$: deviations between observed and predicted RT that contains
- 738 95% of peptides for a given batch of experiment.
- 739 3. Discovery proteomics data
- 740 4. Condensin subunit (NCAPH2) linearity assessment
- 741 5. List of target peptides for PRM and instrument parameters
- 742
- 743

744 **Supplemental Figures:**

- 745 1. Chromatographic retention times of select peptides, showing consistency of RT
746 and adjacency of sample fractions from which they were identified
- 747 2. Scatter plot of experimental and predicted RTs of peptides from experimental
748 batch 2 - 7. *up* = number of unique peptides trained
- 749 3. Functional analysis of biomarkers for enriched cellular components
- 750 4. Normalized peak areas of CNDH2_HUMAN condensin subunit, superimposed
751 with CDS1-SCHPO against increasing concentrations of its heavy-labeled stable
752 isotope standards spiked into a background matrix of plasma.
- 753 5. Flowchart of PRM method development
- 754 6. Differential abundance analysis of validated proteins, showing changes across
755 the three sample collection time points: baseline, post-bypass (P-BP) and post-
756 operative day one (PO1). †: SAA1 and SAA2 could not be distinguished in the
757 validation phase as none of the peptides unique to them met the quantification
758 criteria.

759

760

761

762

763

764

765

766

767 References

- 768 1. Armstrong, S.C., K.L. Cozza, and K.S. Watanabe, *The misdiagnosis of delirium.*
769 *Psychosomatics*, 1997. **38**(5): p. 433-439.
- 770 2. Inouye, S.K., et al., *Nurses' recognition of delirium and its symptoms: comparison of*
771 *nurse and researcher ratings.* *Archives of internal medicine*, 2001. **161**(20): p. 2467-
772 2473.
- 773 3. Ely, E.W., et al., *Current opinions regarding the importance, diagnosis, and management*
774 *of delirium in the intensive care unit: a survey of 912 healthcare professionals.* *Critical*
775 *care medicine*, 2004. **32**(1): p. 106-112.
- 776 4. Brown IV, C.H., *Delirium in the cardiac surgical intensive care unit.* *Current opinion in*
777 *anaesthesiology*, 2014. **27**(2): p. 117.
- 778 5. Inouye, S.K., R.G. Westendorp, and J.S. Saczynski, *Delirium in elderly people.* *The Lancet*,
779 2014. **383**(9920): p. 911-922.
- 780 6. Brown IV, C.H., et al., *The impact of delirium after cardiac surgical procedures on*
781 *postoperative resource use.* *The Annals of Thoracic Surgery*, 2016. **101**(5): p. 1663-1669.
- 782 7. Crocker, E., et al., *Long-term effects of postoperative delirium in patients undergoing*
783 *cardiac operation: a systematic review.* *The Annals of thoracic surgery*, 2016. **102**(4): p.
784 1391-1399.
- 785 8. Newman, M.F., et al., *Longitudinal assessment of neurocognitive function after*
786 *coronary-artery bypass surgery.* *New England Journal of Medicine*, 2001. **344**(6): p. 395-
787 402.
- 788 9. Kálmán, J., et al., *Elevated levels of inflammatory biomarkers in the cerebrospinal fluid*
789 *after coronary artery bypass surgery are predictors of cognitive decline.* *Neurochemistry*
790 *International*, 2006. **48**(3): p. 177-180.
- 791 10. Kozora, E., et al., *Cognitive outcomes after on-versus off-pump coronary artery bypass*
792 *surgery.* *The Annals of thoracic surgery*, 2010. **90**(4): p. 1134-1141.
- 793 11. Saczynski, J.S., et al., *Cognitive trajectories after postoperative delirium.* *N Engl J Med*,
794 2012. **367**(1): p. 30-9.
- 795 12. Rudolph, J.L., et al., *Delirium: an independent predictor of functional decline after*
796 *cardiac surgery.* *Journal of the American Geriatrics Society*, 2010. **58**(4): p. 643-649.
- 797 13. Martin, B.-J., et al., *Delirium: a cause for concern beyond the immediate postoperative*
798 *period.* *The Annals of thoracic surgery*, 2012. **93**(4): p. 1114-1120.
- 799 14. Sugimura, Y., et al., *Risk and consequences of postoperative delirium in cardiac surgery.*
800 *The Thoracic and Cardiovascular Surgeon*, 2020. **68**(05): p. 417-424.
- 801 15. Kishi, Y., et al., *Delirium: patient characteristics that predict a missed diagnosis at*
802 *psychiatric consultation.* *General hospital psychiatry*, 2007. **29**(5): p. 442-445.
- 803 16. de la Cruz, M., et al., *The frequency of missed delirium in patients referred to palliative*
804 *care in a comprehensive cancer center.* *Supportive Care in Cancer*, 2015. **23**(8): p. 2427-
805 2433.
- 806 17. Wiredu, K., et al., *Proteomics for the discovery of clinical delirium biomarkers: A review*
807 *of major contributions.* 2022.

- 808 18. Maldonado, J.R., *Delirium pathophysiology: An updated hypothesis of the etiology of*
809 *acute brain failure*. International Journal of Geriatric Psychiatry, 2018. **33**(11): p. 1428-
810 1457.
- 811 19. Oldham, M.A., J.H. Flaherty, and J.R. Maldonado, *Refining delirium: a transtheoretical*
812 *model of delirium disorder with preliminary neurophysiologic subtypes*. The American
813 Journal of Geriatric Psychiatry, 2018. **26**(9): p. 913-924.
- 814 20. Dillon, S.T., et al., *Higher C-Reactive Protein Levels Predict Postoperative Delirium in*
815 *Older Patients Undergoing Major Elective Surgery: A Longitudinal Nested Case-Control*
816 *Study*. Biol Psychiatry, 2017. **81**(2): p. 145-153.
- 817 21. Lindblom, R.P.F., et al., *Protein Profiling in Serum and Cerebrospinal Fluid Following*
818 *Complex Surgery on the Thoracic Aorta Identifies Biological Markers of Neurologic Injury*.
819 J Cardiovasc Transl Res, 2018. **11**(6): p. 503-516.
- 820 22. Vasunilashorn, S., et al., *A Multi-Protein Signature of Postoperative Delirium*. Innovation
821 in Aging, 2018. **2**(suppl_1): p. 571-572.
- 822 23. van Ton, A.P., et al., *Downregulation of synapse-associated protein expression and loss*
823 *of homeostatic microglial control in cerebrospinal fluid of infectious patients with*
824 *delirium and patients with Alzheimer's disease*. Brain, Behavior, and Immunity, 2020. **89**:
825 p. 656-667.
- 826 24. Vasunilashorn, S., et al., *Proteome-Wide Analysis using SOMAscan Identifies and*
827 *Validates Chitinase-3-Like Protein 1 as a Risk and Disease Marker of Delirium Among*
828 *Older Adults Undergoing Major Elective Surgery*. The Journals of gerontology. Series A,
829 Biological Sciences and Medical Sciences, 2021.
- 830 25. Rhee, J., et al., *Serum Proteomics of Older Patients Undergoing Major Cardiac Surgery:*
831 *Identification of Biomarkers Associated With Postoperative Delirium*. Frontiers in Aging
832 Neuroscience, 2021. **13**: p. 699763.
- 833 26. McKay, T., et al., *Preliminary Study of Serum Biomarkers Associated With Delirium After*
834 *Major Cardiac Surgery*. Journal of Cardiothoracic and Vascular Anesthesia, 2021.
- 835 27. Han, Y., et al., *Proteomic Analysis of Preoperative CSF Reveals Risk Biomarkers of*
836 *Postoperative Delirium*. Front Psychiatry, 2020. **11**: p. 170.
- 837 28. Shaefi, S., et al., *Intraoperative Oxygen Concentration and Neurocognition after Cardiac*
838 *Surgery: A Randomized Clinical Trial*. Anesthesiology, 2021. **134**(2): p. 189-201.
- 839 29. Grassetti, A.V., R. Hards, and S.A. Gerber, *Offline pentafluorophenyl (PFP)-RP*
840 *prefractionation as an alternative to high-pH RP for comprehensive LC-MS/MS*
841 *proteomics and phosphoproteomics*. Analytical and bioanalytical chemistry, 2017.
842 **409**(19): p. 4615-4625.
- 843 30. Ma, C., et al., *Improved peptide retention time prediction in liquid chromatography*
844 *through deep learning*. Analytical chemistry, 2018. **90**(18): p. 10881-10888.
- 845 31. Zou, H. and T. Hastie, *Regularization and variable selection via the elastic net*. Journal of
846 the royal statistical society: series B (statistical methodology), 2005. **67**(2): p. 301-320.
- 847 32. Gerber, S.A., et al., *Absolute quantification of proteins and phosphoproteins from cell*
848 *lysates by tandem MS*. Proceedings of the National Academy of Sciences, 2003. **100**(12):
849 p. 6940-6945.

- 850 33. Kettenbach, A.N., J. Rush, and S.A. Gerber, *Absolute quantification of protein and post-*
851 *translational modification abundance with stable isotope-labeled synthetic peptides.*
852 *Nature protocols*, 2011. **6**(2): p. 175-186.
- 853 34. Geyer, P.E., et al., *Revisiting biomarker discovery by plasma proteomics.* *Mol Syst Biol*,
854 2017. **13**(9): p. 942.
- 855 35. Pol, R.A., et al., *C-reactive protein predicts postoperative delirium following vascular*
856 *surgery.* *Annals of vascular surgery*, 2014. **28**(8): p. 1923-1930.
- 857 36. Liu, X., Y. Yu, and S. Zhu, *Inflammatory markers in postoperative delirium (POD) and*
858 *cognitive dysfunction (POCD): A meta-analysis of observational studies.* *PLoS One*, 2018.
859 **13**(4): p. e0195659.
- 860 37. Peng, J., et al., *Preoperative C-Reactive Protein/Albumin Ratio, a Risk Factor for*
861 *Postoperative Delirium in Elderly Patients After Total Joint Arthroplasty.* *J Arthroplasty*,
862 2019. **34**(11): p. 2601-2605.
- 863 38. Jiang, L. and G. Lei, *Albumin/fibrinogen ratio, an independent risk factor for*
864 *postoperative delirium after total joint arthroplasty.* *Geriatrics & Gerontology*
865 *International*, 2022.
- 866 39. Uhlar, C.M. and A.S. Whitehead, *Serum amyloid A, the major vertebrate acute-phase*
867 *reactant.* *European journal of biochemistry*, 1999. **265**(2): p. 501-523.
- 868 40. Sack, G.H., *Serum amyloid A—a review.* *Molecular Medicine*, 2018. **24**(1): p. 1-27.
- 869 41. Liang, J.-s., et al., *Evidence for local production of acute phase response apolipoprotein*
870 *serum amyloid A in Alzheimer's disease brain.* *Neuroscience letters*, 1997. **225**(2): p. 73-
871 76.
- 872 42. Gabay, C. and I. Kushner, *Acute-phase proteins and other systemic responses to*
873 *inflammation.* *New England journal of medicine*, 1999. **340**(6): p. 448-454.
- 874 43. Barbierato, M., et al., *Expression and differential responsiveness of central nervous*
875 *system glial cell populations to the acute phase protein serum amyloid A.* *Scientific*
876 *reports*, 2017. **7**(1): p. 1-14.
- 877 44. Facci, L., et al., *Serum amyloid A primes microglia for ATP-dependent interleukin-1β*
878 *release.* *Journal of Neuroinflammation*, 2018. **15**(1): p. 1-11.
- 879 45. Jang, W.Y., et al., *Overexpression of serum amyloid a 1 induces depressive-like behavior*
880 *in mice.* *Brain Research*, 2017. **1654**: p. 55-65.
- 881 46. Jang, S., et al., *Serum amyloid A1 is involved in amyloid plaque aggregation and memory*
882 *decline in amyloid beta abundant condition.* *Transgenic Research*, 2019. **28**(5): p. 499-
883 508.
- 884 47. Matsumoto, J., et al., *Serum amyloid A-induced blood-brain barrier dysfunction*
885 *associated with decreased claudin-5 expression in rat brain endothelial cells and its*
886 *inhibition by high-density lipoprotein in vitro.* *Neuroscience Letters*, 2020. **738**: p.
887 135352.
- 888 48. Zhang, Y., et al., *Elevated Serum Amyloid A Is Associated With Cognitive Impairment in*
889 *Ischemic Stroke Patients.* *Frontiers in Neurology*, 2021. **12**.
- 890 49. Mueller-Stainer, S., et al., *Anti-amyloidogenic and neuroprotective functions of cathepsin*
891 *B: implications for Alzheimer's disease.* *Neuron*, 2006. **51**(6): p. 703-714.
- 892 50. Sundelöf, J., et al., *Higher cathepsin B levels in plasma in Alzheimer's disease compared*
893 *to healthy controls.* *Journal of Alzheimer's Disease*, 2010. **22**(4): p. 1223-1230.

- 894 51. Rong, X., et al., *Chronic periodontitis and Alzheimer disease: a putative link of serum*
895 *proteins identification by 2D-DIGE proteomics*. *Frontiers in aging neuroscience*, 2020: p.
896 248.
- 897 52. Hook, V., et al., *Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic*
898 *brain injury, and related brain disorders*. *Biochimica et Biophysica Acta (BBA)-Proteins*
899 *and Proteomics*, 2020. **1868**(8): p. 140428.
- 900 53. Hook, G., V. Hook, and M. Kindy, *The cysteine protease inhibitor, E64d, reduces brain*
901 *amyloid- β and improves memory deficits in Alzheimer's disease animal models by*
902 *inhibiting cathepsin B, but not BACE1, β -secretase activity*. *Journal of Alzheimer's*
903 *disease*, 2011. **26**(2): p. 387-408.
- 904 54. Barrett, A.J., J.F. Woessner, and N.D. Rawlings, *Handbook of Proteolytic Enzymes,*
905 *Volume 1*. Vol. 1. 2012: Elsevier.
- 906 55. Haj-sheykholeslami, A., et al., *Serum pepsinogen I, pepsinogen II, and gastrin 17 in*
907 *relatives of gastric cancer patients: comparative study with type and severity of gastritis*.
908 *Clinical Gastroenterology and Hepatology*, 2008. **6**(2): p. 174-179.
- 909 56. He, C.y., et al., *Serum pepsinogen II: a neglected but useful biomarker to differentiate*
910 *between diseased and normal stomachs*. *Journal of gastroenterology and hepatology,*
911 2011. **26**(6): p. 1039-1046.
- 912 57. Cao, X.-Y., et al., *Serum pepsinogen II is a better diagnostic marker in gastric cancer*.
913 *World journal of gastroenterology: WJG*, 2012. **18**(48): p. 7357.
- 914 58. Huang, Y.-k., et al., *Significance of serum pepsinogens as a biomarker for gastric cancer*
915 *and atrophic gastritis screening: a systematic review and meta-analysis*. *PloS one*, 2015.
916 **10**(11): p. e0142080.
- 917 59. Thayer, J.F., *Vagal tone and the inflammatory reflex*. *Cleveland Clinic journal of*
918 *medicine*, 2009. **76**: p. S23-6.
- 919 60. Cerejeira, J., et al., *The cholinergic system and inflammation: common pathways in*
920 *delirium pathophysiology*. *Journal of the American Geriatrics Society*, 2012. **60**(4): p.
921 669-675.
- 922 61. Weber, C.S., et al., *Low vagal tone is associated with impaired post stress recovery of*
923 *cardiovascular, endocrine, and immune markers*. *European journal of applied*
924 *physiology*, 2010. **109**(2): p. 201-211.
- 925 62. Johnson, R.L. and C.G. Wilson, *A review of vagus nerve stimulation as a therapeutic*
926 *intervention*. *Journal of inflammation research*, 2018. **11**: p. 203.
- 927 63. Janowitz, H.D. and F. Hollander, *Relation of uropepsinogen excretion to gastric pepsin*
928 *secretion in man*. *Journal of Applied Physiology*, 1951. **4**(2): p. 53-56.
- 929 64. Rolfson, D.B., et al., *Incidence and risk factors for delirium and other adverse outcomes*
930 *in older adults after coronary artery bypass graft surgery*. *The Canadian journal of*
931 *cardiology*, 1999. **15**(7): p. 771-776.
- 932 65. O'neal, J.B., et al., *Risk factors for delirium after cardiac surgery: a historical cohort study*
933 *outlining the influence of cardiopulmonary bypass*. *Canadian Journal of*
934 *Anesthesia/Journal canadien d'anesthésie*, 2017. **64**(11): p. 1129-1137.
- 935 66. Ordóñez-Velasco, L.M. and E. Hernández-Leiva, *Factors associated with delirium after*
936 *cardiac surgery: a prospective cohort study*. *Annals of Cardiac Anaesthesia*, 2021. **24**(2):
937 p. 183.

- 938 67. Norkiene, I., et al., *Incidence and precipitating factors of delirium after coronary artery*
939 *bypass grafting*. Scandinavian Cardiovascular Journal, 2007. **41**(3): p. 180-185.
- 940 68. Bucarius, J., et al., *Predictors of delirium after cardiac surgery delirium: effect of beating-*
941 *heart (off-pump) surgery*. The Journal of thoracic and cardiovascular surgery, 2004.
942 **127**(1): p. 57-64.
- 943 69. Banfi, C., et al., *Proteomic analysis of plasma from patients undergoing coronary artery*
944 *bypass grafting reveals a protease/antiprotease imbalance in favor of the serpin α 1-*
945 *antichymotrypsin*. Journal of proteome research, 2010. **9**(5): p. 2347-2357.
- 946 70. Clendenen, N., et al., *Correlation of pre-operative plasma protein concentrations in*
947 *cardiac surgery patients with bleeding outcomes using a targeted quantitative*
948 *proteomics approach*. PROTEOMICS—Clinical Applications, 2017. **11**(7-8): p. 1600175.
- 949 71. Fong, T.G., et al., *Identification of Plasma Proteome Signatures Associated With Surgery*
950 *Using SOMAscan*. Ann Surg, 2021. **273**(4): p. 732-742.
- 951 72. Holmes, C., et al., *Systemic inflammation and disease progression in Alzheimer disease*.
952 *Neurology*, 2009. **73**(10): p. 768-774.
- 953 73. Vasunilashorn, S.M., et al., *Cytokines and postoperative delirium in older patients*
954 *undergoing major elective surgery*. Journals of Gerontology Series A: Biomedical
955 *Sciences and Medical Sciences*, 2015. **70**(10): p. 1289-1295.
- 956 74. Oh, E.S., et al., *Sex differences in hip fracture surgery: preoperative risk factors for*
957 *delirium and postoperative outcomes*. Journal of the American Geriatrics Society, 2016.
958 **64**(8): p. 1616-1621.
- 959 75. Kotfis, K., et al., *The practical use of white cell inflammatory biomarkers in prediction of*
960 *postoperative delirium after cardiac surgery*. Brain Sciences, 2019. **9**(11).
- 961 76. Liotta, L.A. and E.F. Petricoin, *Mass Spectrometry–Based Protein Biomarker Discovery:*
962 *Solving the Remaining Challenges to Reach the Promise of Clinical Benefit*. Clinical
963 *chemistry*, 2010. **56**(10): p. 1641-1642.
- 964 77. Rifai, N., M.A. Gillette, and S.A. Carr, *Protein biomarker discovery and validation: the*
965 *long and uncertain path to clinical utility*. Nat Biotechnol, 2006. **24**(8): p. 971-83.
- 966 78. Paulovich, A.G., et al., *The interface between biomarker discovery and clinical validation:*
967 *the tar pit of the protein biomarker pipeline*. PROTEOMICS—Clinical Applications, 2008.
968 **2**(10-11): p. 1386-1402.
- 969 79. Whiteaker, J.R., et al., *An automated and multiplexed method for high throughput*
970 *peptide immunoaffinity enrichment and multiple reaction monitoring mass*
971 *spectrometry-based quantification of protein biomarkers*. Molecular & Cellular
972 *Proteomics*, 2010. **9**(1): p. 184-196.
- 973 80. Shaefi, S., et al., *Intraoperative oxygen concentration and neurocognition after cardiac*
974 *surgery: study protocol for a randomized controlled trial*. Trials, 2017. **18**(1): p. 600.
- 975 81. Eng, J.K., T.A. Jahan, and M.R. Hoopmann, *Comet: an open-source MS/MS sequence*
976 *database search tool*. Proteomics, 2013. **13**(1): p. 22-24.
- 977 82. Sanner, M.F., *Python: a programming language for software integration and*
978 *development*. J Mol Graph Model, 1999. **17**(1): p. 57-61.
- 979 83. R Core Team, *R: A Language and Environment for Statistical Computing*, in *R Foundation*
980 *for Statistical Computing*. 2013: Vienna, Austria.

- 981 84. Ward Jr, J.H., *Hierarchical grouping to optimize an objective function*. Journal of the
982 American statistical association, 1963. **58**(301): p. 236-244.
- 983 85. MacLean, B., et al., *Skyline: an open source document editor for creating and analyzing*
984 *targeted proteomics experiments*. Bioinformatics, 2010. **26**(7): p. 966-968.
985





Figure 1






Figure 3




Figure 4






Figure 5





Supplemental Figure 2

